These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15711498)

  • 1. Natalizumab (Tysabri) for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 2005 Feb; 47(1202):13-5. PubMed ID: 15711498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP
    Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for multiple sclerosis?
    Drug Ther Bull; 2008 Sep; 46(9):69-72. PubMed ID: 18784381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Natalizumab (Tysabri) prescription practices of neurologists in southern France].
    Rocher F; Cohen M; Lebrun C
    Rev Neurol (Paris); 2010 Apr; 166(4):412-8. PubMed ID: 19846185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of natalizumab for formulary consideration.
    Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
    Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
    Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
    Berger JR
    Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
    Balcer LJ; Galetta SL; Calabresi PA; Confavreux C; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA
    Neurology; 2007 Apr; 68(16):1299-304. PubMed ID: 17438220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Natalizumab (Tysabri)].
    Ravnborg M
    Ugeskr Laeger; 2007 Sep; 169(38):3184-7. PubMed ID: 17910826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA; Sandrock A
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple sclerosis: between wish and reality].
    Kümpfel T; Hohlfeld R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():83-5. PubMed ID: 15968879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
    Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drugs; natalizumab].
    van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.